HistoRx, Inc. Patent applications |
Patent application number | Title | Published |
20140142101 | CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB - Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers. | 05-22-2014 |
20130344510 | IDENTIFICATION OF CANCER PATIENTS LIKELY TO BENEFIT FROM RADIATION THERAPY - Disclosed herein are methods of identifying suitable patients for postoperative radiotherapy based on the discovery that the quantification of ER, beyond simple positive/negative characterization, can provide valuable predictive information for the treatment of cancer, specifically breast cancer, and more particularly may predict a group more likely to respond to RT and spare patients from a potentially harmful treatment. Furthermore, the true quantification of ER expression provides a continuous recurrence risk assessment for patients being treated with tamoxifen, and therefore the standardization of the data across sites and imaging platforms significantly reduces the misclassification of patients when compared to the current standard by which ER expression is determined. | 12-26-2013 |
20130310268 | METHOD AND SYSTEM FOR STANDARIZING MICROSCOPE INSTRUMENTS - Methods and apparatus for standardizing quantitative measurements from a microscope system. The process includes a calibration procedure whereby an image of a calibration slide is obtained through the optics of the microscope system. The calibration slide produces a standard response, which can be used to determine a machine intrinsic factor for the particular system. The machine intrinsic factor can be stored for later reference. In use, images are acquired of a target sample and of the excitation light source. The excitation light source sample is obtained using a calibration instrument configured to sample intensity. The calibration instrument has an associated correction factor to compensate its performance to a universally standardized calibration instrument. The machine intrinsic factor, sampled intensity, and calibration instrument correction factor are usable to compensate a quantitative measurement of the target sample in order to normalize the results for comparison with other microscope systems. | 11-21-2013 |
20130310267 | QUANTITATIVE METHODS AND KITS FOR PROVIDING REPRODUCIBLE IHC4 SCORES - The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient. | 11-21-2013 |
20130216111 | COMPARTMENT SEGREGATION BY PIXEL CHARACTERIZATION USING IMAGE DATA CLUSTERING - The present invention relates generally to improved methods of defining areas or compartments within which biomarker expression is detected and quantified. In particular, the present invention relates to automated methods for delineating marker-defined compartments objectively with minimal operator intervention or decision making. The method provides for precise definition of tissue, cellular or subcellular compartments particularly in histological tissue sections in which to quantitatively analyzing protein expression. | 08-22-2013 |
20130143763 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 06-06-2013 |
20100062452 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 03-11-2010 |